Fig. 4: Associations of CD27 mRNA expression with prognosis and immunotherapy response in independent melanoma cohorts.

A Kaplan–Meier survival curve depicting overall survival in 54 stage IV melanoma patients (GSE22153) stratified by high and low CD27 mRNA expression. B Overall Survival (OS) Kaplan-Meier curve for 91 immunotherapy-treated melanoma patients (PRJEB23709), stratified by CD27 mRNA expression (FPKM) at the median cut-off of 1.221 (High >= 1.220795; Low < 1.220795). C Progression-free survival (PFS) Kaplan–Meier curve for 91 immunotherapy-treated melanoma patients (PRJEB23709), stratified by CD27 mRNA expression (FPKM) using the median cut-off of 1.220795 (High >= 1.220795; Low < 1.220795). D Box plot shows the mRNA expression level of CD27 between poor and good responders (PRJEB23709). E The ROC curve demonstrating the ability of CD27 mRNA expression, B cell, TLS and IFNγ signatures to predict immunotherapy response in 91 melanoma patients (PRJEB23709). F OS Kaplan–Meier curve for 51 immunotherapy-treated melanoma patients (GSE91061), stratified by gene expression (FPKM) using the ROC-optimized cut-off of 7.738 (High > = 7.738; Low < 7.738). G Box plot shows the mRNA expression level of CD27 between poor and good responders (GSE91061). H The ROC curve demonstrating the ability of CD27 mRNA expression, B cell, TLS and IFNγ signatures, and TMB to predict immunotherapy response in 51 melanoma patients treated with immunotherapy (GSE91061). I Kaplan-Meier survival curve depicting progression-free survival in 102 melanoma patients treated with immunotherapy (FAHZZU) stratified by high and low CD27 mRNA expression by qRT-PCR. J Box plot showing differential expression of CD27 (qRT-PCR) between poor and good responders. K The ROC curve demonstrating the ability of CD27 mRNA expression (qRT-PCR) to predict immunotherapy response in the FAHZZU cohort. *p < 0.05, **p < 0.01, ****p < 0.0001.